Vanda Pharmaceuticals Inc [VNDA] stock is trading at $7.71, up 3.21%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VNDA shares have gain 4.05% over the last week, with a monthly amount glided 13.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vanda Pharmaceuticals Inc [NASDAQ: VNDA] stock has seen the most recent analyst activity on November 05, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $11. Previously, H.C. Wainwright started tracking the stock with Buy rating on October 31, 2024, and set its price target to $18. On July 11, 2024, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $11 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $12 on February 25, 2022. BofA Securities initiated its recommendation with a Buy and recommended $22 as its price target on May 12, 2021. Citigroup downgraded its rating to Neutral for this stock on January 14, 2021, but kept the price target unchanged to $14. In a note dated October 29, 2020, Citigroup upgraded an Buy rating on this stock but restated the target price of $14.
Vanda Pharmaceuticals Inc [VNDA] stock has fluctuated between $3.81 and $9.60 over the past year. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Vanda Pharmaceuticals Inc [NASDAQ: VNDA] shares were valued at $7.71 at the most recent close of the market. An investor can expect a potential return of 75.1% based on the average VNDA price forecast.
Analyzing the VNDA fundamentals
Vanda Pharmaceuticals Inc [NASDAQ:VNDA] reported sales of 212.07M for the trailing twelve months, which represents a growth of 18.06%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.17 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Vanda Pharmaceuticals Inc’s Current Ratio is 3.12. In addition, the Quick Ratio stands at 3.10 and the Cash Ratio stands at 0.59. Considering the valuation of this stock, the price to sales ratio is 2.15, the price to book ratio is 0.98.
Transactions by insiders
Recent insider trading involved Polymeropoulos Mihael Hristos, President and CEO, that happened on Aug 07 ’25 when 10000.0 shares were purchased. Director, Mitchell Stephen Ray completed a deal on Jun 13 ’25 to sell 7000.0 shares. Meanwhile, Director Mitchell Stephen Ray bought 7000.0 shares on Jun 13 ’25.
